We believe this site might serve you best:

United States

English Continue

This country code will remain if no action is taken to change it.

Don't see your country?
Promega Corporation

Dr. Terry Riss, Promega Corporation, Madison

Nanoluc® Luciferase: A Smaller, Brighter & More Versatile Luciferase Reporter


NanoLuc® Luciferase, a 19kDa, monomeric luciferase gives a brighter signal and enables more sensitive measurement. The NanoLuc®/Nano-Glo® Assay is ~100-fold brighter than either firefly or Renilla luciferase in vitro and in cells. This seminar will introduce the characteristics and uses of NanoLuc® Luciferase and considerations for choosing Firefly or NanoLuc® Luciferase. Applications of NanoLuc® Luciferase as a fusion partner will be described including protein translocation and degradation.

Dr Terry Riss started the Cell Biology program at Promega Corporation in 1990. He has since held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Specialist, Cell Health involved in outreach educational training activities. Dr. Riss regularly participates in NIH study sections reviewing HTS grants and is co-editor of the cell culture assays section of the Assay Guidance Manual hosted by the NIH.

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.